(Total Views: 497)
Posted On: 06/05/2019 5:51:20 PM
Post# of 30066
.jpg)
From the Todos presentation.
Post AMBS acquisition, a total of 158M shares( we have 49.99% but will have less post exercise of warrants and Nasdaq IPO)
Lympro "pilot" studies to begin in 2020 (I guess IUO?)
Lympro PET data to be published in journal
File new IP and target markets outside US
Todos Cancer diagnostics need to run trial in US, with other data supporting FDA package.
Nasdaq targeted Q319, with spending on continued development and trials to follow.
Very clean deck and good presentation from Dr. Weiss.
Question from audience about marketing to public. Dr. Weiss reiterates goal is gold standard companion diagnostics. Audio suggested decent size and enthusiastic audience.
Post AMBS acquisition, a total of 158M shares( we have 49.99% but will have less post exercise of warrants and Nasdaq IPO)
Lympro "pilot" studies to begin in 2020 (I guess IUO?)
Lympro PET data to be published in journal
File new IP and target markets outside US
Todos Cancer diagnostics need to run trial in US, with other data supporting FDA package.
Nasdaq targeted Q319, with spending on continued development and trials to follow.
Very clean deck and good presentation from Dr. Weiss.
Question from audience about marketing to public. Dr. Weiss reiterates goal is gold standard companion diagnostics. Audio suggested decent size and enthusiastic audience.
(6)
(0)
